No Data
FRONTAGE (01521.HK) was increased shareholding by Hongkong Tigermed Co., Limited by 1.064 million shares.
On January 3, Glory Holdings reported that according to the latest equity disclosure data from the Stock Exchange, on December 31, 2024, FRONTAGE (01521.HK) was increased by Hongkong Tigermed Co., Limited in the market, acquiring 1.064 million shares at an average price of HKD 1.773 per share, involving approximately HKD 1.1865 million. After the shareholding increase, the latest number of shares held by Hongkong Tigermed Co., Limited is 1,079,664,090 shares, with the shareholding ratio rising from 52.98% to 53.04%.
Highly resilient! Leading CRO companies have stabilized their fundamentals, but the shadow of the biosafety bill may still linger next year | Year-end review.
① In 2024, the USA Biodefense Act will disrupt CROs throughout the year and may continue next year; ② In the first three quarters of this year, over half of listed companies experienced revenue growth, and leading CROs demonstrated resilience; ③ Research on popular targets such as ADC, GLP-1, and bispecific antibodies will continue to be hot; ④ In 2025, the performance of leading CROs and small to medium enterprises may further diverge.
Frontage Holdings Announces Hong Kong Office Relocation
The U.S. bioterrorism law has undergone significant changes, the CRO concept has launched a major counterattack, and WuXi AppTec is excited!
Industry pessimistic expectations may improve.
How to break through the challenges in the development of innovative drugs? The industry suggests focusing on internationalization.
① The year 2024 will be the inaugural year of large-scale authorized trade, and going abroad has become an important direction for the development of local pharmaceutical companies; ② Chinese企业品牌, clinical trial capabilities, data presentation formats, and levels of international operation still need time and practical verification.
Hong Kong stock abnormal | CRO concept stocks rebounded in the morning, overseas investment and financing gradually recovered. The pharmaceutical subdivision field and emerging businesses are expected to develop rapidly.
Concept stocks of CRO rebounded in early trading. As of the time of writing, Genscript Bio (01548) rose by 4.39% to HK$10.94; Tigermed (03347) rose by 4.47% to HK$33.85; Frontage (01521) rose by 2.75% to HK$1.12; Joinn Laboratories (06127) rose by 2.49% to HK$9.47; Wuxi Bio (02269) rose by 1.68% to HK$14.54.
Despite Hitting HK$1.67, Frontage Holdings Insiders Still Sold Too Soon
No Data
